PATENT CLAIM ANALYSIS

Application Number: 15764969
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["435", "006100"]

Abstract:
Therapeutic treatments for cancer based on mutations in the TP53 gene are disclosed, including pharmaceutical corn-positions and methods of using pharmaceutical compositions for treating a disease, in particular a cancer. Diagnostic methods for determining mutations in the TP53 gene are also disclosed.

Claim (Index 19):
The composition of  claim 15 , wherein the active pharmaceutical ingredient is a mTOR inhibitor, and wherein the mTOR inhibitor is selected from the group consisting of trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexanecarboxylic acid (OSI-027), sapanisertib, omipalisib, dactolisib, everolimus, temsirolimus, sirolimus, and pharmaceutically acceptable salts, solvates, hydrates, cocrystals, or prodrugs thereof.

Metadata:
- Claim Count in Document: 31.0
- Percentile: 90.0
- Lexical Diversity: 1.53333
- Patent Class: 435.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15319740', '15112968', '15101864', '15516780', '13403856']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6604620752682205
- 35 USC 102 Novelty (BERT): 0.5026326991366894
- Combined Prediction Score: 0.6446791376550675
- Mean Citation Score: 218.288076
- Max Citation Score: 231.69904
- Similarity Product: 139.24538048008918

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test